Nonprofit · EIN 26-4510094
TARGETCANCER FOUNDATION INC
Tax-exempt · CAMBRIDGE, MA 02139
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| January 31, 2025 | 990 | $1,261,609 | $839,048 | $422,561 | $1,016,178 | $0 | $1,016,178 |
| January 31, 2024 | 990 | $676,451 | $797,674 | -$121,223 | $523,908 | $0 | $523,908 |
Financial details: 990 for the year ended January 31, 2025
Revenue
- Contributions, gifts and grants
- $1,308,131
- Program service revenue
- $0
- Investment income
- $29,761
- Net income from fundraising events
- -$76,283
- Other revenue
- -$76,283
Expenses
- Grants and similar amounts paid
- $0
- Compensation of officers, directors and key employees
- $243,322
- Other salaries and wages
- $128,132
- Salaries, compensation and benefits (total)
- $402,014
- Professional fundraising fees
- $0
- Accounting fees
- $13,678
- Occupancy
- $22,981
- Travel
- $4,461
- Depreciation
- $3,134
- Program services (functional)
- $508,441
- Management and general (functional)
- $222,602
- Fundraising (functional)
- $108,005
Balance sheet and other
- Total assets, start of year
- $523,908
- Total assets, end of year
- $1,016,178
- Total liabilities, end of year
- $0
- Net assets, end of year
- $1,016,178
- Net assets without donor restrictions
- $974,770
- Net assets with donor restrictions
- $41,408
- Gross receipts
- $1,372,762
- Employees
- 4
- Volunteers
- 30
- Year formed
- 2009
- State of legal domicile
- MA
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended January 31, 2025, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| James M Palma | Chief Executive Officer Trustee or director, Officer | 50 | $168,555 | $5,502 |
| Kristen Palma | President/Director Trustee or director, Officer | 40 | $55,397 | $11,933 |
| Jerry Alderman | Director Trustee or director | 1 | $0 | $0 |
| Jennifer Levin Carter MD | Director Trustee or director | 1 | $0 | $0 |
| CJ Chapman | Director Trustee or director | 1 | $0 | $0 |
| Samuel Davenport | Director Trustee or director | 1 | $0 | $0 |
| Janet Fine MS | Director Trustee or director | 1 | $0 | $0 |
| Mary Pat Lancelotta | Director Trustee or director | 1 | $0 | $0 |
| Kristen Schuler Scammon | Director Trustee or director | 1 | $0 | $0 |
| Andrea Sullivan | Director Trustee or director | 1 | $0 | $0 |
| Colin Carey | Treasurer/Director Trustee or director, Officer | 1 | $0 | $0 |
990 for the year ended January 31, 2024: 11 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| James M Palma | Chief Executive Officer Trustee or director, Officer | 50 | $163,594 | $1,396 |
| Kristen Palma | President/Director Trustee or director, Officer | 40 | $39,931 | $13,946 |
| Jerry Alderman | Director Trustee or director | 1 | $0 | $0 |
| Jennifer Levin Carter MD | Director Trustee or director | 1 | $0 | $0 |
| CJ Chapman | Director Trustee or director | 1 | $0 | $0 |
| Samuel Davenport | Director Trustee or director | 1 | $0 | $0 |
| Janet Fine MS | Director Trustee or director | 1 | $0 | $0 |
| Mary Pat Lancelotta | Director Trustee or director | 1 | $0 | $0 |
| Kristen Schuler Scammon | Director Trustee or director | 1 | $0 | $0 |
| Andrea Sullivan | Director Trustee or director | 1 | $0 | $0 |
| Colin Carey | Treasurer/Director Trustee or director, Officer | 1 | $0 | $0 |
Address and contacts
- Address (IRS master file)
- 955 MASSACHUSETTS AVE STE 343, CAMBRIDGE, MA 02139-3233
- In care of
- % JIM PALMA
- Principal officer (990 for 2024)
- James Palma, 955 Massachusetts Avenue 343, Cambridge, MA 02139
- Signed the 990
- James Palma, Chief Executive Officer
- Phone
- (617) 765-4881
- Website
- www.targetcancer.org
- Return prepared by
- Baker Newman & Noyes
Mission
TargetCancer Foundation promotes the development of lifesaving treatment protocols for rare cancers. TargetCancer Foundation directly supports initiatives at the forefront of cancer treatment by funding innovative research, fostering collaborations, and raising awareness among scientists, clinicians, and patients.
Program accomplishments
- The specific purposes of the Organization are to raise awareness of and support for research into rare cancers, and to directly support patients and families facing rare cancers. This was accomplished in the fiscal year through the ongoing operation of a rare cancer precision medicine clinical trial, and through other programs. In 2020, TargetCancer Foundation launched a rare cancer precision medicine clinical trial called TCF-001 TRACK (Target Rare Cancer Knowledge). TRACK is a 400-patient clinical trial studying genomics and precision medicine in rare cancers, providing patients with critical personalized genomic data about their cancer and treatment recommendations from a panel of field leaders, and also generating rare cancer research data. TRACK is developed, sponsored and managed by TargetCancer Foundation, and is currently over halfway through its enrollment of patients with rare cancers and cancer of unknown primary.In 2024, TargetCancer Foundation held a major scientific meeting- the Think Tank on Advancing Precision Medicine in Rare Cancers. This unique, innovative meeting unites key stakeholders including clinicians, researchers, government, industry, and patients and advocates. This meeting is specifically designed to promote collaboration, information-sharing and idea generation in an effort to define research priorities, foster new collaborative efforts across institutions, and ultimately propel the field forward.In 2024, TargetCancer Foundation launched its Patient Outreach, Education and Support Program, which provides online and downloadable educational resources designed for patients navigating a rare cancer diagnosis. Theis includes resources such as What is a Rare Cancer, Initial Steps for Navigating a Rare Cancer Diagnosis, Clinical Trials, and Biomarker Testing. In addition, this program includes an educational webinar series intended for patients and caregivers.Expenses $508,441
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in January, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | January 31, 2026 | June 15, 2026 | Not on file |
| 2024 | January 31, 2025 | June 16, 2025 | 990 on file |
| 2023 | January 31, 2024 | June 17, 2024 | 990 on file |
IRS record
- EIN
- 26-4510094
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (170(b)(1)(A)(vi))
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 2009
- Accounting year ends
- January
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Medical research (H30)
- Assets (IRS master file)
- $1,016,178
- Income (IRS master file)
- $1,372,762
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | January 2025 | $1,261,609 | $839,048 | $1,016,178 | XML |
| 990 | January 2024 | $676,451 | $797,674 | $523,908 | XML |
| 990 | January 2023 | $846,106 | $704,653 | $645,131 | IRS |
| 990 | January 2022 | – | – | – | IRS |
| 990 | January 2021 | – | – | – | IRS |
| 990 | January 2020 | – | – | – | IRS |
| 990 | January 2019 | – | – | – | IRS |
| 990 | January 2018 | – | – | – | IRS |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 26-4510094).
Questions about TARGETCANCER FOUNDATION INC
- What is the EIN of TARGETCANCER FOUNDATION INC?
- The employer identification number (EIN) of TARGETCANCER FOUNDATION INC is 26-4510094.
- Is TARGETCANCER FOUNDATION INC tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2009.
- Are donations to TARGETCANCER FOUNDATION INC tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does TARGETCANCER FOUNDATION INC file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of TARGETCANCER FOUNDATION INC due?
- The return for tax year 2025 (the year ending January 31, 2026) is due June 15, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did TARGETCANCER FOUNDATION INC last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended January 2025.
- Who is the principal officer of TARGETCANCER FOUNDATION INC?
- The 990 for the year ended January 31, 2025 names James Palma.
- Who are the officers and directors of TARGETCANCER FOUNDATION INC?
- The 990 for the year ended January 31, 2025 lists 11 people; 2 received compensation from the organization, the highest $168,555 (James M Palma, Chief Executive Officer).
- How much revenue does TARGETCANCER FOUNDATION INC have?
- On its 990 for the year ended January 31, 2025 it reported revenue of $1,261,609, expenses of $839,048 and total assets of $1,016,178 at year end.
Other nonprofits in CAMBRIDGE
- BROAD INSTITUTE INC EIN 26-3428781 · last filed 990 for 2025
- WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH EIN 06-1043412 · last filed 990 for 2025
- LIFE SCIENCE CARES INC EIN 81-2435939 · last filed 990 for 2024
- COUNT ME IN INC EIN 83-0561457 · last filed 990 for 2023
- CENTER FOR HUMAN GENETICS INC EIN 04-3154223 · last filed 990 for 2025
- ACTIVE SITE RESEARCH INC EIN 93-2180352 · last filed 990 for 2025
- INTREPID ALLIANCE INC EIN 35-2711268 · last filed 990 for 2024
- COLLABORATIVE TRAJECTORY ANALYSIS PROJECT EIN 93-4558784 · last filed 990 for 2024
All nonprofits in CAMBRIDGE · Massachusetts · Medical research